Liminal Biosciences Inc

NASDAQ:LMNL  
0.41
-0.01 (-2.38%)
Business Deals, Earnings Announcements

Liminal Biosciences Announces Termination Of Legacy CDMO Contract

Published: 08/25/2022 11:31 GMT
Liminal Biosciences Inc (LMNL) - Liminal Biosciences Announces Termination of Legacy Cdmo Contract.
Liminal Biosciences Inc - Termination Results in Anticipated Cash Savings of $33.1 Million.
Liminal Biosciences Inc - Termination Removes Last of Legacy Contracts Associated With Former Plasma-derived Therapeutics Business.
Liminal Biosciences Inc - Under Terms of Termination Agreement, Liminal Biosciences Will Pay a Total of $18 Million.
Liminal Biosciences - Will Make 2 Further Payments of Which $3.4 Million Will Be Payable in Q1 of 2023, Remaining $3.4 Million Will Be Payable in Q1 of 2024.
Revenue is expected to be $0.16 Million
Adjusted EPS is expected to be -$0.31

Next Quarter Revenue Guidance is expected to be $0.57 Million
Next Quarter EPS Guidance is expected to be -$0.16

More details on our Analysts Page.